Back

Comparison of dapagliflozin 10 mg versus empagliflozin 10 mg in heart failure patients without type 2 diabetes mellitus on top of triple guideline-directed medical therapy

18 May 2025 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Novel insights into heart failure therapeutics Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Inci Tugce Colluoglu

Dokuz Eylul University, Izmir (Turkiye)

5 More presentations in this session

Presentation thumbnail
Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan
Doctor C. Morbach (Wuerzburg, DE)
Abstract Slides Video
Presentation thumbnail
Impact of vericiguat use in real life. New insight of the VERITA registry.
Doctor M. Groba Marco (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Start as we mean to go on - when aggression is the answer, assessing the impact of setting of heart failure diagnosis on number of pillars at optimisation
Doctor N. Melarkey (Newry, GB)
Abstract Slides Video
Presentation thumbnail
Tricuspid regurgitation is a barrier to guideline-directed medical therapy implementation in patients with acute decompensated heart failure and reduced ejection fraction
Doctor D. Cocianni (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Effect of obesity on the implementation of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction
Doctor T. Gergely (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insights into heart failure therapeutics

The Event

Event poster

Heart Failure 2025

18 May 2025 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources